The ability to analyze cryopreserved peripheral blood mononuclear cell (PBMC) from biobanks for antigen-specific immunity is necessary to evaluate response to immune-based therapies. To ensure comparable assay results, collaborative research in multicenter trials needs reliable and reproducible cryopreservation that maintains cell viability and functionality. A standardized cryopreservation procedure is comprised of not only sample collection, preparation and freezing but also low temperature storage in liquid nitrogen without any temperature fluctuations, to avoid cell damage. Therefore, we have developed a storage approach to minimize suboptimal storage conditions in order to maximize cell viability, recovery and T-cell functionality.
Introduction
Cryopreservation of PBMC is commonly used to preserve cells for prospective phenotypic and functional analysis in a wide range of infectious diseases and clinical vaccine studies. An increasing number of investigations have focused on diseases affecting cellular immunity, including HIV [28, 44] , tuberculosis [37] and cancer [15] , using PBMC for assay readout. In the context of vaccine and pathogenesis studies, effective and reproducible cryopreservation protocols for PBMC enable the setup of large sample repositories which in turn allows comparative multi-center studies and avoids inter-and intra-laboratory assay variability during analysis of independently isolated fresh samples [38] . Accurate quantification of cellular immune responses is important in such studies because changes in the antigen-specific T-cell response indicate the efficiency of a new test vaccine as it affects the initiation of antibody synthesis and cellular immune responses. However, the time interval for reliable results after PBMC isolation is quite narrow [5] . This makes comparison of results between laboratories difficult and, following Luyet and Hodapp [26] , has led to the continuous development of new cryopreservation methods have been continuously developed. At temperatures below À130°C, metabolic activity is significantly reduced and cells can theoretically be stored for long periods without effects on properties and function [18] .
Suboptimal cryopreservation results in a significant decrease of cell viability and number, and may also cause alterations of the cellular phenotype and a reduction of the immunogenic response to specific antigens [6, 22, 24, 29, 32, 34, 46, 48] . Cryopreservation can affect antigen processing capability and cause a disproportionate loss of responses to protein antigens [27] . There is also a relationship between post-thawing viability and the capacity for functional responses [48] . However, preservation of antigen-specific T-cell response is under permanent critical discussion. Moreover, the most common used method of freezing PBMC, fetal calf serum (FCS) supplemented with 10% dimethyl sulfoxide (DMSO) is under constant discussion by regulatory authorities [23, 25] , as there is the risk of transmitting potentially infectious agent [4, 50] . It can also influence immunologic assessment studies done following thawing [3] . Ideally, media should be non-toxic, standardized and free of all undefined additives and possible sources of contamination and there have been an increasing number of attempts to create such standardized cryomedia [10, 14, 36] . The cell mediated immune response is not only influenced by the composition of the cryomedia, but also by multiple factors which impact on PBMC quality from the time collection to sample testing. Numerous studies have focused on the influence of freezing and thawing procedures on PBMC quality for cell-based assay applications [1, 2, 10, 11, 22, 35, 40, 41, 48] . Not only the sample processing and the freezing process are important for good sample cryopreservation, but also maintenance of optimal storage conditions, especially during long-term storage, is also critical. It is generally acknowledged that cell viability improves with decreasing temperatures [45] and many groups have analyzed the influence of the storage temperature and storage time on cell viability and T-cell functionality [13, 22, 31, 36, 40, 47] . Sample pre-freezing preparation, freezing procedures and the post-freezing treatment are normally controlled, but sample storage, under conventional conditions in a normal liquid nitrogen freezer, can be undefined and uncontrolled with temperature fluctuations occurring during sample transfer to the liquid nitrogen tank, sample storage, sample sorting and sample removal. There is a lack of data showing the effect of such multiple temperature changes during sample storage and their impact on cell viability, recovery and functionality.
In order to better understand the impact of such multiple temperature fluctuations on cell quality, we stored the PBMC from 10 different donors under suboptimal storage condition with temperature fluctuations and compared this to optimal storage conditions without temperature shifts, or sample storage simulating the use of a protective hood system to minimize the increase in temperature [19] . Automated trypan blue dye exclusion and IFN-c ELISpot were used to measure cell viability, recovery, and functionality after cryopreservation in the standardized xeno-free cryomedium IBMT I and cell storage under 3 different conditions.
The study shows that multiple temperature shifts, caused by sample storage, sorting and removal, minimize PBMC viability, PBMC recovery and T-cell functionality as measured by IFN-c ELISpot.
Material and methods

PBMC isolation
Buffy coat samples of 10 healthy, CMV sero-positive donors were obtained from the blood donor center ''Blutspendezentrale Saar-Pfalz gGmbh Am Klinikum Saarbruecken'' (Saarbruecken). Blood donors gave written informed consent that the buffy coats can be used for research purposes. A specific ethics statement for blood collections is not necessary for blood donor centers according to German national regulations.
Peripheral blood mononuclear cells (PBMC) were isolated from citrated blood by density gradient centrifugation over lymphocyte separation medium (PAA, Cölbe). The buffy coat layers were collected, pooled and washed with PBS (Gibco, Karlsruhe). Contaminating red blood cells were lysed using Pharm Lyse (BD, Heidelberg) by incubating 2 Â 10 8 cells in 
Cryopreservation
For cryopreservation, the PBMC were frozen in the xeno-free cryomedium IBMT I (Procryotect, Ruedlingen, Switzerland) at a final concentration of 10 Â 10 6 cell/ml. Aliquots of 1 ml cell suspension were immediately transferred to pre-cooled (À20°C) cryovials (Sarstedt, Nürnbrecht), placed in a frozen thermal pack (À20°C) during the aliquoting process, transferred into a pre-cooled (+4°C) freezing isopropanol container (VWR, Darmstadt; cooling rate of 1°C/min) to allow a controlled rate of freezing from +4°C to À80°C for 24 h prior to transfer into storage in the vapor phase of liquid nitrogen at À135°C.
Storage and transfer conditions
We used 3 different storage conditions for the cryopreserved PBMC.
Sample storage in the gas phase of liquid nitrogen (N2) without any temperature changes PBMC were stored in the vapor phase of liquid nitrogen (Biosafe 420 MD (Cryotherm)) without any temperature rises during the storage process (N2). The liquid nitrogen freezer was connected to an automated fill system with an external alarm system to alert in the case of temperature failure.
The other storage conditions both mimicked the sample storage and sample removal processes for biobanking or clinical trials.
Sample storage and removal within a protective hood (+PHS)
Samples were cycled 400Â with the use of a protective hood system (+PHS). The protective hood system is located on the top of the cryogenic storage tank and comprises an isolated cryogenic workspace. The workspace was cooled down to À80°C with adsorbed liquid nitrogen as cooling media in the surrounding walls, so that the atmosphere inside the workspace was cold and dry. The samples were allowed to equilibrate at À80°C for ca. 5 min. The temperature inside the sample was measured by a type T thermo element (reaction time 0.5 s) and reached a temperature of À102°C.
Sample storage and removal without a protective hood (ÀPHS)
Samples was cycled 400Â without a protective hood system (ÀPHS). In this case, the outside environment temperature was room temperature (+20°C). The samples were allowed to equilibrate at room temperature for ca. 5 min. The temperature inside of the sample was again measured by a type T thermo element and reached a temperature of À60°C.
Temperature cycling was performed using a controlled robot system ( Fig. 1 ) and the test cycle is described in detail in Fig. 2 .
The sample transport was performed without disruption of the cooling chain (Fig 3) . The sample storage rack containing the samples was taken out and situated on the top of the other storage racks inside of the storage tank beside a transport vessel filled with liquid nitrogen. The samples of interest were transferred in the transport vessel. The vessel was transported to a cooled working bench. Inside of this cooled atmosphere the samples were arranged in the sample cabinet dedicated for the robot system. Afterwards, the sample cabinet was transferred into the cooled transfer vessel. The transport vessel then was transported to the cooled protective hood system over the robot system and the sample cabinet was fixed. After cycling the samples were transported in the reversed order to the storage tank. The samples were stored in the vapor phase of liquid nitrogen (Biosafe 420 MD (Cryotherm)) without any further temperature rises until analysis.
Thawing PBMC
RPMI 1648 medium (Gibco, Karlsruhe) was supplemented with 25 mM HEPES buffer 1 mM L-glutamine (Gibco, Karlsruhe), 1Â Penicillin/Streptomycin (Cölbe, PAA) and 10% heat-inactivated fetal calf serum. 8 ml were aliquoted into 50 ml polypropylene tubes (Sarstedt, Nürnbrecht) and warmed to 37°C. Upon removal from liquid nitrogen storage, no more than two cryovials at a time were thawed in a 37°C water bath until the cell suspension was melting and a little ice remained. One ml of warmed media was slowly added to the thawed PBMC and the cell suspension had been transferred to a corresponding polypropylene tube (final volume 10 ml). The tubes were centrifuged at 400 g for 5 min at room temperature. The PBMC were resuspended in 10 ml medium per 1 Â 10 7 cells and transferred in a cell incubator (5% CO 2 , 37°C) overnight with the cap of the tube loose.
Determination of cell recovery and cell viability
The effect of the 3 different storage conditions on cell recovery was evaluated using the ViCell cell analyser (Beckman Coulter, Krefeld). Five samples per donor per storage condition were thawed and cell recovery and viability measured immediately post-thaw and again after overnight culture using the trypan blue dye exclusion test. Each sample was measured three times.
Cell recovery and cell viability were calculated in the following way Recovery (%) (after thawing):
% recovery ¼ ðnumber of viable PBMC after thawing=number of frozen viable PBMCÞ Â 100
Recovery (%) (after overnight culture):
% recovery ¼ ½number of viable PBMC after overnight rest =ðnumber of frozen viable PBMC À number of viable PBMC removed for measurement directly after thawingÞ Â 100 Viability:
% viability ¼ ðnumber of viable PBMC=number of total PBMCÞ Â 100 Fig. 1 . System structure. The figure shows the setup for the cycling process. The robot is programmed to change the vertical position along the temperature gradient in the tube. A reference sensor controls the movements which correlate to the desired temperatures. Fig. 2 . Cycling process. The figure shows the flow diagram of the cycle mimicking process. The samples wait at the turn points to reach the desired temperatures. The waiting time at the upper temperature limit is determined in a reference sample of similar thermal properties. The holding time at the lower limit temperature was 900 s. The holding time at the higher temperature limit was 5 min. The temperatures inside the sample was À102°C (+PHS) and À60°C (ÀPHS), respectively. 
Determination of T-cell functionality
PBMC were assayed for IFN-c production in the presence of CMV pp65 peptide pool (BD Bioscience, Heidelberg), CEF peptide pool (CTL, Bonn), PHA (Sigma-Aldrich, Taufkirchen) and background control (culture media containing 0.4% DMSO) in triplicates. 96 well plate anti-human-IFN-c mAb 1-D1k precoated (Mabtech, Hamburg) were washed four times with PBS (Gibco, Karlsruhe) and blocked with culture medium, RPMI 1648 medium (Gibco, Karlsruhe) containing 25 mM HEPES buffer 1 mM L-glutamine (Gibco, Karlsruhe), 1Â Penicillin/Streptomycin (Cölbe, PAA) and 10% heat-inactivated fetal calf serum, for 30 min. Cryopreserved PBMC were thawed as described above and used the next day. Approximately 1 Â 10 5 PBMC were added to the CEF, CMV and background wells and 0.5 Â 10 5 PBMCs to the PHA wells. CEF peptides and CMV peptides were added to a final concentration of 2 lg/ml/peptide and 1.75 lg/ ml/peptide, respectively. The final PHA concentration was 4 lg/ml.
The final DMSO concentration was between 0.1% and 0.25%. The plates were incubated at 37°C, 5% CO 2 for 20-22 h. After washing the plates five times with PBS the production of IFN-c by T-cells was measured by addition of 1:200 diluted HRP-labeled detection mAb 7-B6-1 (Mabtech, Hamburg) in sterile filtered PBS containing 0.5% FCS. After incubation, the plates were washed five times with PBS. The spots were developed using Nova Red Substrate Kit (Vector, CA). Spot development was stopped after approximately 2 min by extensively washing with distilled water. The spots were evaluated with the Immunopspot Analyser (CTL, Bonn). The results were expressed as spot forming cells (SFC per million PBMC).
Statistic
For analysis of cell recovery and viability, results are expressed as mean ± standard deviation. As a Gaussian distribution cannot be assumed using different blood donors, comparisons of the cell storage without any temperature fluctuation (N2) in relation to sample storage with the use of a protective hood system (+PHS) and without the use of the protective hood system (ÀPHS) were validated using the Wilcoxon Signed-Rank Test, a non-parametric statistical hypothesis test. The PBMC recovery and viability was considered to be statistically significant equal or different with a p-value <0.05.
Measurement of the environment
The measurement field was in a heat insulated test field with a transparent hood and a liquid nitrogen storing basin (heat insulated basin). The level of liquid nitrogen (LN 2 ) was controlled by the BioSafe controller and automatically filled if the LN 2 level fell under a specific level (Fig. 1) . The following basic concepts have been applied for the system design and development (Table 1) . Proper modifications have been adopted for each simulation case. At the top of the temperature-gradient tube was an electric heater and at the bottom, the liquid nitrogen. In this case the temperature distribution between À196°C and 40°C rises with elevation on the temperature-gradient tube, where the required temperature (for example, À170°C, À80°C) was controlled.
The robot moved the sample between the low temperatures and the relatively higher temperatures within the temperaturegradient tube. The cycling process is described in detail in Fig. 2 . The sample cabinet could hold up to 10 cell test samples, 1 dummy sample with and one dummy sample without a temperature sensor for the control of boundary conditions, while the cycling was performed using the controlled robot system.
Results
PBMC recovery and viability
PBMC from 10 CMV seropositive healthy donors were cryopreserved in cryomedium IBMT I and stored under three different conditions: sample storage in the vapor phase of liquid nitrogen without any temperature fluctuation (N2), sample storage using a protective hood system to avoid temperature fluctuations during sample storage and removal (+PHS) and sample storage without the use of the protective hood system (ÀPHS). From each donor 5 samples of each storage condition were thawed and analyzed for cell recovery (Table 2 , supplementary data) and cell viability (Table 3 , supplementary data) using the trypan blue dye exclusion method directly after thawing and after overnight culture.
The mean recovery immediately after thawing was 94.34% (±8.11%) (N2), 93.85% (±6.52%) (+PHS) and 89.34% (±7.22%) (ÀPHS) (Fig. 4) . Fig. 4 . PBMC recovery. Comparison of PBMC recovery using three different storage conditions. Samples were analyzed directly after thawing and after overnight culture. The mean values (with standard deviation) of PBMC were presented from 10 different blood donors. N2: sample storage without temperature rises, +PHS: sample storage mimicking 400 cycles of sample storage and removal with the use of a protective hood system, ÀPHS: sample storage mimicking 400 cycles of sample storage and removal without the use of a protective hood system, ⁄ : statistical different (p 6 0.05).
The recovery immediately after thawing was greater than observed after overnight culturing of the PBMC. We detected a mean PBMC recovery of 82.65% (±9.50%), 81.65% (±8.80%) and 69.15% (±12.69%) using the storage conditions N2, +PHS and ÀPHS, respectively (Fig. 4) .
Statistical analysis using the Wilcoxon Signed-Rank test showed that there were no significant differences in PBMC recovery of sample storage without temperature shifts (N2) and sample storage using the protective hood system, when measured either directly after cell thawing or after overnight cell culture. In contrast, there were statistical significant reductions (p < 0.005) in PBMC recovery detectable using sample storage without the use of the protective hood system (ÀPHS) in comparison to sample storage without any temperature shifts (N2) at both measurement points.
The mean PBMC viability was greater than 94% after thawing and 90% after overnight culture for all three storage conditions used (Fig. 5) . The mean viability immediately after thawing was 97.37% (±0.59%), 97.46% (±0.65%) and 94.59% (±2.52%) of the initially cryopreserved PBMC using the storage condition N2, +PHS and ÀPHS, respectively (Fig. 5) .
The viability immediately after thawing was greater than observed after overnight culture of the PBMC with a mean PBMC viability of 94.28% (±1.37%) (N2), 94.46% (±1.25%) (+PHS) and 90.89% (±2.76%) (ÀPHS).
Statistical analysis using the Wilcoxon Signed-Rank test showed that there was no statistically significant difference between sample storage with the protective hood system (+PHS) and PBMC storage without temperature rises (N2) either directly after thawing or after overnight cell culture. In contrast, cyclical temperature shifts to room temperature (ÀPHS) led to a statistical significant reduction of cell viability (p < 0.005) at both measurement points in time in comparison to using the protective hood system (+PHS) or sample storage without any temperature increase (N2).
Characterization of T-cell response by IFN-c ELISpot
We could demonstrate that PBMC storage using a protective hood system to avoid temperature fluctuations during sample storage and removal resulted in similar cell recovery and cell viability compared to sample storage without any temperature shifts. In contrast, sample storage in which temperature fluctuations up to a recorded temperature of À60°C led to loss in PBMC recovery and viability.
Since the maintenance of T-cell responses during cryopreservation is one of the most important parameters in clinical trials, it is very important to detect and understand the potential impact of different storage conditions on T-cell functionality. Therefore, PBMC cryopreserved in cryomedium IBMT I and stored at different storage conditions (N2, +PHS, ÀPHS) were tested in IFN-c ELISpot using CMV and CEF peptide pools as immunogenic antigens (Table 2, Fig. 6 ).
To classify positive responses, the average number of spot forming cells (SFC) per 10 6 PBMC was determined; three replicates were used for this calculation. Following ''Standardization and Validation Issues of ELISpot Assay'' [20] we used the definition of responder R > 4D and R > 55 (R is the reagent SFC/10 6 PBMC, D corresponding to SFC for medium (background)). Using the definition above 9/10 PBMC samples were responsive to the CMV and 9/10 to the CEF peptide pool ( Table 2) , independent of the storage condition. Also, with 0-12 spot-forming cells per 10 6 PBMC, the background was very low, independent of the sample storage (data not shown).
The results indicated that repeated temperature fluctuation during sample storage decreases the antigen-specific immune response of T-cells measured by IFN-c ELISpot (Fig. 7) . We detected only a small decrease in T-cell functionality using the protective hood system. Using this system we detected a mean reduction of À6.54% (±15.89) in response to CEF peptide pool antigen-stimulation, ranging from +5.60% to À37.85% for different donors. A similar average decrease of À4.36% (±8.24) in T-cell function after T-cell stimulation using the CMV peptide pool was also detectable. The differences in CMV specific immune responses ranged from +6.25% to À15.12%. In contrast, a strong reduction in the immune response was detected for samples exposed to temperature fluctuations, with cyclical temperature rises towards room temperature, when compared to samples stored without any temperature cycling. Repeated sample storage and removal without the use of the protected hood system led to an average decrease of À29.71% (±25.36) in response to the CEF peptide pool and À28.02% (±20.69) after antigene stimulation with the CMV peptide pool as. In comparison, in samples stored without temperature fluctuation the reduction ranged from +3.09% to À44.38% and from À0.89% to À66.24% in response to the CEF and CMV peptide pool, respectively.
In summary, these results show that the maintenance of cell viability, recovery and T-cell functionality is strongly dependent on maintaining the samples in storage conditions without temperature fluctuations. Repeated temperature shifts led to a decrease in all measured parameters.
Discussion
Cryopreservation of cells offers many advantages to the research community, such as banking of multiple aliquots of cells from multicenter studies of large cohorts of individuals. It allows precious samples to be available for future studies, often using newly developed techniques or assays. Additionally, samples of the same donor banked over time can be simultaneously processed, allowing greater inter-and intra-laboratory control and reducing costs. High-quality and reproducible cryopreservation of specimens is extremely important and demanding for the success of these studies. Cryopreservation can have significant effects and on PBMC viability, recovery and functionality [39, 49] and many parameters are known to influence recovery including population purity, processing time, freezing medium, thawing and overnight culture conditions [5, 9, 12, 14, 21, 24, 36] . Previous studies have reported that PBMC cryopreserved in liquid nitrogen can provide good recovery and viability for use in immunophenotype analysis [22, 24, 30] and that such conditions do not significantly affect the level of apoptosis [33] . In contrast, other investigators have shown a loss of T-cell response to antigenic stimulation [31] , while cryopreservation has been shown to induce apoptosis [16] . In addition, sample storage at À30°C, or temperature rises mimicking sample transport conditions, have been shown to lead to a reduction in T-cell functionality [40] and cell damage [13] .
Despite such investigations, there is a lack of data about the influence of temperature rises during sample storage, sorting and removal, if specimens are cryopreserved in conventional liquid nitrogen tanks without a protective hood system to guard against temperature fluctuations. Our studies provide additional information that the quality of sample storage and handling is critical for maintaining PBMC viability, PBMC recovery and T-cell functionality. Exposure of cryopreserved PBMC to suboptimal sample storage with repeated temperature fluctuations can lead to a reduction in sample quality. We have demonstrated that temperature shifts during storage reduce cell recovery and viability as measured by trypan blue dye exclusion and could resulted in significant cell death, especially after overnight culture. Other groups have also reported a reduction in cell viability after culture compared to immediately post thaw, suggesting that a population of cells still undergoes apoptosis or necrosis following thawing [21, 31] . Smith et al. (2007) showed an increase in the percentage of apoptotic cells after cyclical temperature rises and programmed cell death can be induced by physiological signals or by a number of physical events like heat shock, free radicals, UV light and gamma radiation [43] . Cells can also receive signals that make them predisposed to apoptosis but they do not actually undergo cell death until the final signal is received [7, 8, 17] . Suboptimal cryopreservation may prime the cells for the apoptotic pathway, without initiating the process. Overnight culture of the cryopreserved cells in the presence of mitogens, that are known to exist in fetal calf serum, could trigger the primed cells into the death cascade [13, 51, 52] .
We have also demonstrated that cyclical temperature rises during the storage process decrease T-cell functionality after stimulation with CEF and CMV peptide pools. Mimicking sample storage, sample sorting and sample removal processes that use a protective hood system increased the T-cell response by about 23% in comparison to the same procedures without protective hood system. The degree of reduction in T-cell functionality ranged from 0% to T-cell functionality. Reduction of T-cell functionality after cyclic sample storage and removal by use of the protective hood system (+PHS) and without the protective hood system (ÀPHS). T-cell response was measured by INF-c ELISpot using CEF and CMV peptide pool.
74% and was donor-dependent and not predictable. For that reason it was not possible to apply a correction factor to the results received from the immune assays. However, our results are in agreement with those of other investigators who have detected a reduced immune response in ELISpot assay after stimulation with mitogens and T-cell specific antigens of cells after having subjected them to storage at À20°C and temperature changes mimicking sample transport conditions on dry ice [40] . It is known that cryopreservation of lymphocytes may have effects on cell surface molecules of T-cells such CCR5 and CD45 RA/RO and may decrease response to infectious diseases and recall antigens [6] in both HIV-infected and non-infected blood donors. Furthermore, cryopreservation can modify the ability of T-cells to secrete cytokines. Freezing and thawing cells significantly altered the cytokine secretion of cells [24, 42] . Cyclical temperature increase during sample storage could have similar effects. In summary, we have investigated the influence of cyclical temperature fluctuations on PBMC health and have demonstrated that small cyclical temperature rises during the storage process in liquid nitrogen induced by sample storage, sorting and removal, leads to decreased cell recovery, cell viability and T-cell functionality.
Retrospective sample analysis is commonly used in clinical programs including studies for infectious diseases, malaria, and cancer. In addition, samples from clinical trial will often be allocated and stored in central cryorepositories under low temperature condition in liquid nitrogen. These studies show the impact of sample storage conditions on the integrity and quality of the cryopreserved samples and the resulting data analysis.
Further investigations will be necessary to determine of the minimal number of temperature fluctuations during the storage process that lead to the beginning of the negative biological effects. The knowledge of this critical number of temperature rises could be used as an additional sample quality indicator. Beside the avoidance of temperature fluctuations during the sample storage, the opening of the storage tanks and the resultant temperature rises should be monitored and documented to use this data as a supplemental quality parameter.
